Amgen Inc (AMGN) stock
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3023% above fair value
$435.64−3.18 (-0.72%)
Close on Nov 20, 2026Market cap $235.52BP/E 25.3Yield 2.22%
Amgen free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Amgen's free cash flow for the twelve months ending Sep 30, 2026 was $9.58B, down 17.0% year over year. For fiscal 2025 it was $8.10B, down 22.1% from the year before. Over ten years it grew -1.2% a year on average. The highest annual figure on record is $10.56B in fiscal 2018.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.10B | -22.1% |
| FY2024 | Dec 31, 2024 | $10.39B | +41.2% |
| FY2023 | Dec 31, 2023 | $7.36B | -16.2% |
| FY2022 | Dec 31, 2022 | $8.79B | +4.8% |
| FY2021 | Dec 31, 2021 | $8.38B | -15.2% |
| FY2020 | Dec 31, 2020 | $9.89B | +15.9% |
| FY2019 | Dec 31, 2019 | $8.53B | -19.2% |
| FY2018 | Dec 31, 2018 | $10.56B | +0.4% |
| FY2017 | Dec 31, 2017 | $10.51B | +9.3% |
| FY2016 | Dec 31, 2016 | $9.62B | +5.2% |
| FY2015 | Dec 31, 2015 | $9.14B | +11.0% |
| FY2014 | Dec 31, 2014 | $8.23B | +47.1% |
| FY2013 | Dec 31, 2013 | $5.60B | +7.8% |
| FY2012 | Dec 31, 2012 | $5.19B | +14.1% |
| FY2011 | Dec 31, 2011 | $4.55B | -12.6% |
| FY2010 | Dec 31, 2010 | $5.21B | -10.3% |
| FY2009 | Dec 31, 2009 | $5.81B | +9.2% |
| FY2008 | Dec 31, 2008 | $5.32B | +28.6% |
| FY2007 | Dec 31, 2007 | $4.13B | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $3.65B | -14.0% |
| Q2 FY2026 | Jun 30, 2026 | $3.49B | +82.6% |
| Q1 FY2026 | Mar 31, 2026 | $1.48B | +50.7% |
| Q4 FY2025 | Dec 31, 2025 | $961.00M | -78.2% |
| Q3 FY2025 | Sep 30, 2025 | $4.25B | +28.2% |
| Q2 FY2025 | Jun 30, 2025 | $1.91B | -14.0% |
| Q1 FY2025 | Mar 31, 2025 | $980.00M | +113.5% |
| Q4 FY2024 | Dec 31, 2024 | $4.40B | +1422.5% |
| Q3 FY2024 | Sep 30, 2024 | $3.31B | +31.9% |
| Q2 FY2024 | Jun 30, 2024 | $2.22B | -42.1% |
| Q1 FY2024 | Mar 31, 2024 | $459.00M | -36.3% |
| Q4 FY2023 | Dec 31, 2023 | $289.00M | -87.5% |
| Q3 FY2023 | Sep 30, 2023 | $2.51B | -10.9% |
| Q2 FY2023 | Jun 30, 2023 | $3.84B | +127.9% |
| Q1 FY2023 | Mar 31, 2023 | $720.00M | -63.5% |
| Q4 FY2022 | Dec 31, 2022 | $2.31B | -8.4% |
| Q3 FY2022 | Sep 30, 2022 | $2.82B | +45.4% |
| Q2 FY2022 | Jun 30, 2022 | $1.68B | -14.9% |
| Q1 FY2022 | Mar 31, 2022 | $1.97B | -38.9% |
| Q4 FY2021 | Dec 31, 2021 | $2.52B | -6.1% |
| Q1 FY2021 | Mar 31, 2021 | $1.94B | -2.7% |
| Q4 FY2020 | Dec 31, 2020 | $1.98B | +55.9% |
| Q3 FY2020 | Sep 30, 2020 | $3.23B | +87.0% |
| Q2 FY2020 | Jun 30, 2020 | $2.68B | -9.6% |
| Q1 FY2020 | Mar 31, 2020 | $1.99B | -35.8% |
| Q2 FY2019 | Jun 30, 2019 | $1.27B | -33.7% |
| Q1 FY2019 | Mar 31, 2019 | $1.73B | -32.8% |
| Q4 FY2018 | Dec 31, 2018 | $2.97B | +3.8% |
| Q3 FY2018 | Sep 30, 2018 | $3.10B | -5.9% |
| Q2 FY2018 | Jun 30, 2018 | $1.92B | -10.6% |
| Q1 FY2018 | Mar 31, 2018 | $2.57B | +16.0% |
| Q4 FY2017 | Dec 31, 2017 | $2.86B | -0.5% |
| Q3 FY2017 | Sep 30, 2017 | $3.30B | +32.1% |
| Q2 FY2017 | Jun 30, 2017 | $2.14B | -14.0% |
| Q1 FY2017 | Mar 31, 2017 | $2.22B | – |
| Q4 FY2016 | Dec 31, 2016 | $2.87B | – |
| Q3 FY2016 | Sep 30, 2016 | $2.50B | – |
| Q2 FY2016 | Jun 30, 2016 | $2.49B | – |
See a number that looks wrong?